Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

BioPheresis Awarded Grant for Development of its Cancer Therapy

  • BioPheresis was awarded a two-year, EUR 500,000 grant  to accelerate and expand work on a new cancer treatment with the company’s OncoSorb® column from the German federal government.

    “Initial study data and the present decision of the German Federal Ministry of Education and Research indicate that our company and the OncoSorb® therapy have the potential to make a difference in the treatment of cancer patients,” says Bernhard Ehmer, CEO and managing director.

    This approach of cancer therapy uses an immuno-adsorptive treatment with established apheresis procedures to combat metastatic cancers, explains BioPheresis. By the application of an immuno-affinity (OncoSorb) column, soluble tumor necrosis factor receptors (sTNFRs) and soluble interleukin-2 alpha receptor (sIL-2Ra) were removed from patients’ blood. Depletion of these immuno-inhibitory factors allows the body’s own immune response to attack and destroy tumors once again, as in a well working immune system when TNF mediates destruction of transformed cells, notes a BioPheresis spokesperson.

    “We look forward to obtaining the CE-mark as the next step and are planning a study in metastatic breast cancer to generate more data to confirm the existing results,” adds Ehmer.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »